Key result
In an isolated rat heart model, the administration of glycated albumin suppressed the cardioprotective effects induced by xamoterol during reperfusion.
Why the study?
Do advanced-glycation end products (AGEs) suppress cardioprotection induced by beta1-adrenergic preconditioning in an isolated rat heart model?
Do advanced-glycation end products (AGEs) suppress cardioprotection induced by beta1-adrenergic preconditioning in an isolated rat heart model?
Advanced-glycation end products suppress beta1-adrenergic preconditioning in isolated rat hearts, potentially explaining the loss of ischemic preconditioning in diabetic myocardium.
Answers are grounded in this paper and cite their sources.
Does not support practice changes in diabetes; leaves open whether AGEs blunt beta1-preconditioning in humans.
Ischemic heart disease in diabetic patients might be linked to the accumulation of advanced-glycation end products (AGEs). In ischemic rat hearts, expression of receptor for AGEs and its ligands is significantly enhanced and involved in cardiac ischemia/reperfusion (I/R) injury even in the absence of diabetes. It has recently been reported that diabetic human myocardium cannot be protected by preconditioning. In this context, our hypothesis was that beta1-adrenergic preconditioning might be altered in the presence of AGEs. Using an isolated non-working rat heart model, this study investigated the effect of AGEs on cardioprotection induced by transient beta1-adrenoceptor (beta1-AR) stimulation with xamoterol (Xa). After 6-hydroxydopamine (6-OHDA) pre-treatment and a 20-min stabilization period, hearts were perfused at constant pressure for 20 min, then subjected to 40 min of global ischemia and 30 min of reperfusion (I/R, Ctrl); and exposed to 0.01 microm Xa for 5 min framed with or without 15.2 microm albumin (Alb) or glycated albumin (Gly Alb). The main endpoints were the mean coronary flow (MCF), the left ventricular end-diastolic pressure (LVEDP), rate-pressure product (RPP) and creatine kinase (CK) release and necrosis area. XA induced an increase in the MCF after I/R (t = 85 min), a protective effect on the LVEDP, an improvement in RPP, a decrease of CK release during reperfusion and a reduction of necrotic area. The beneficial effects induced by Xa during reperfusion were suppressed by the administration of Gly Alb during Xa infusion, whereas Alb did not hamper Xa-induced protection. These results suggest that AGEs suppress the cardioprotection resulting from the activation of beta1-ARs and thus might contribute to cardiovascular damages seen in diabetic patients.
No takes yet. Share an insight, caveat, or question.
Robinet et al. (2006) studied Ischemia/reperfusion injury. Glycated albumin (Gly Alb) during xamoterol (Xa) infusion vs. Albumin (Alb) or no albumin (Ctrl) was evaluated on Mean coronary flow, left ventricular end-diastolic pressure, rate-pressure product, creatine kinase release, and necrosis area. In an isolated rat heart model, the administration of glycated albumin suppressed the cardioprotective effects induced by xamoterol during reperfusion.
Synapse has enriched 10 related papers. Consider them for comparative context: